Business
RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin
RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin.
About this update from Replicel Life Sciences Inc.
[{"type":"text","content":"\n \n \n RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin\n \n \nRepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin\n\nPhase 1 clinical trial investigating the use of a patient-specific cell-based dermal rejuvenation product (RCS-01) is scheduled to deliver data in late 2016\n\n \n VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec 17, 2015) - RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSX VENTURE:RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced that the first injections of study products have been completed in the phase 1 clinical study (NCT02391935) evaluating RCS-01, an autologous cell-based skin rejuvenation product. RepliCel is developing RCS-01 as a longer-lasting, more natural alternative to existing dermal fillers on the market which often have only short-term results. \n RepliCel's RCS-01 cell therapy uses a participant's own replicated fibroblast cells, isolated from their hair follicles, to rebuild the collagen, elastin and other glycoproteins that provide structural support and stability to the skin's extracellular matrix - intended to return skin back to its youthful appearance.\n The single-centre study, being conducted in Germany, will evaluate the safety and tolerability of injecting RCS-01 into adult patients with aged and wrinkled skin. \n \"I am very pleased with the speed and efficiency with which the Düsseldorf team has been able to recruit participants for our RCS-01 trial,\" commented Darrell Panich, Vice President of Clinical Affairs. \"Their efforts have allowed us to complete the first injections this week and have over half of the study compliment provide biopsies before the end of 2015. This will allow for study products to be manufactured during the Christmas break and for more injections to take place in the New Year. With their continued diligence, we anticipate a conclusion of the recruitment phase of the trial in early 2016.\" \n Dr. Rolf Hoffmann, RepliCel's Chief Medical Officer, added: \"The treatment of our first participants in this trial is a significant step in the clinical development of RCS-01 as we explore the product's ability to restore the dermal matrix of the skin. We believe RCS-01 ...